NCT02716805 2022-10-12Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell TransplantLudwig Institute for Cancer ResearchPhase 1 Terminated6 enrolled 11 charts